Hormone replacement therapy doesn’t lead to breast cancer reoccurrence

Credit: CC0 Public Domain

New paper in Journal of the National Cancer Institutepublished by Oxford University Press, found that menopausal hormone therapy for breast cancer survivors was not associated with breast cancer recurrence, despite concerns among some researchers and doctors.

Go out hot and sweaty at night, too vaginal dryness same to you urinary tract infectionsepidemic breast cancer survivors frequently. These symptoms worsen the quality of life and can cause patients to quit medicine. These symptoms can be reduced by vaginal estrogen therapy or menopause hormone therapy. However, the safety of systemic and vaginal estrogen use among breast cancer survivors, particularly those with estrogen receptor-positive disease, is unclear.

Many doctors have warned breast cancer survivors against using menopausal hormone therapy after two trials in the 1990s showed an increased risk of breast cancer recurrence. Although previous studies have not shown an increase in recurrence, such studies have limitations, including small sample sizes and short follow-up periods.

Researchers here investigated the association between hormonal therapy and the risk of breast cancer recurrence and mortality in a large group of Danish postmenopausal women treated with estrogen receptor-positive breast cancer.

The study included longitudinal data from a national cohort of postmenopausal women, diagnosed between 1997 and 2004 with primary breast cancer who had not received treatment or five years of hormone therapy, as verified from the Danish medical register. .

Of the 8,461 women who did not receive vaginal estrogen or menopausal hormone therapy before breast cancer diagnosis, 1,957 and 133 used vaginal estrogen or menopausal hormone therapy, respectively, after diagnosis. . The researchers here found no increase in the risk of recurrence or mortality for those who received either vaginal estrogen therapy or menopausal hormone therapy.

Elizabeth Cathcart-Rake, who wrote an editorial to follow the story. “These results suggest that breast cancer survivors on tamoxifen with severe genitourinary disease can take vaginal estrogen therapy without an increase in their risk of breast cancer recurrence. However, caution is advised when considering vaginal estrogen for breast cancer patients. aromatase inhibitorsor when considering menopausal hormonal therapy.”

For postmenopausal women, vaginal estrogens do not cause the risk of cancer, other diseases

More information:
Søren Cold et al, Systemic or vaginal hormone regulation after primary breast cancer: a Danish cohort study, JNCI: Journal of the National Cancer Institute (2022). DOI: 10.1093/jnci/djac112

Its availability
Oxford University Press

hintHormone replacement therapy does not cause breast cancer recurrence (2022, July 20) Retrieved July 20, 2022 from

This document is subject to copyright. Except for any bona fide transaction for research or investigation purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.

Hormone replacement therapy doesn’t lead to breast cancer reoccurrence Source link Hormone replacement therapy doesn’t lead to breast cancer reoccurrence

Related Articles

Back to top button